Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibrance-3: ALKS 2680 in Idiopathic Hypersomnia
NCT06843590Phase 2Active, not recruiting
- Sponsor
- Alkermes
- Start
- May 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of alixorexton in idiopathic hypersomnia (IH), sponsored by Alkermes. Started May 2025; status: active, not recruiting.
02
Drugs
alixorexton
03
Conditions
idiopathic hypersomnia (IH)
Beyond the preview
Go deeper on NCT06843590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843590.